Status:
COMPLETED
ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19
Lead Sponsor:
Neuromed IRCCS
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
Hypothesis Very recent evidences supports the hypothesis that the novel coronavirus 2019 (2019-nCoV) uses the SARS-1 (severe acute respiratory syndrome ) coronavirus receptor angiotensin converting e...
Detailed Description
Background Very recent evidences support the hypothesis that the novel coronavirus 2019 (2019-nCoV) uses the SARS-1 coronavirus receptor ACE2 for gains entry into target cells. Angiotensin receptor-bl...
Eligibility Criteria
Inclusion
- Patients hospitalized for COVID-19
Exclusion
- none
Key Trial Info
Start Date :
March 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
3400 Patients enrolled
Trial Details
Trial ID
NCT04318418
Start Date
March 23 2020
End Date
June 30 2020
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Neuromed, Department of Epidemiology and Prevention
Pozzilli, Italy, 86077